EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Epidemiology and Survival of Marginal Zone Lymphoma in Colombian Patients: An Observational Retrospective Study

Juan F Combariza-Vallejo iD, Rocío Orduz-Rodriguez iD, Natalia Gomez-Lopera iD, Claudia C Colmenares-Mejia iD, Monica S Benavides-Rojas, Yesica M Calderon-Ortega, Marcela Godoy-Corredor, Mario Arturo Isaza-Ruget

JCO Global Oncology · 2025

DOI: 10.1200/go-24-00495 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Juan F Combariza-Vallejo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Hematología, Clinica Universitaria Colombia, Clinica Colsanitas S.A., Grupo Keralty, Bogotá, Colombia. Hauptthemen laut MEDLINE: Lymphoma, B-Cell, Marginal Zone. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Marginal zone lymphomas (MZLs) are indolent non-Hodgkin lymphomas, categorized into three subtypes: extranodal, splenic, and nodal MZL (NMZL). MZL epidemiology and outcomes in Latin America remain underexplored. MATERIALS AND METHODS This retrospective cohort study included patients with MZL in Colombia from 2000 to 2023. Patients were followed for at least 24 months from diagnosis. The primary outcomes were real-world overall survival (Rw-OS) and real-world progression-free survival (Rw-PFS). RESULTS The cohort included 103 patients (63.1% female, 36.9% male) with a median age of 61.8 years. MALT lymphoma was the most common subtype (61.1%), followed by splenic MZL (26.2%) and NMZL (12.7%). The 60-month Rw-OS was 86.4%, and the Rw-PFS was 77.2%. CONCLUSION MZL in Colombian patients exhibits varied clinical presentations and survival outcomes. This study underscores the importance of early detection and subtype-specific management of MZL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, B-Cell, Marginal ZoneHumansFemaleMaleRetrospective StudiesColombiaMiddle AgedAgedAdultAged, 80 and over

Autor:innen und Institutionen

  • Servicio de Hematología, Clinica Universitaria Colombia, Clinica Colsanitas S.A., Grupo Keralty, Bogotá, Colombia.
  • Laboratorio Clínico y de Patología, Clinica Colsanitas S.A., Grupo Keralty, Bogotá, Colombia.
  • Unidad de investigación, Fundación Universitaria Sanitas, Grupo de investigación INPAC, Bogotá, Colombia.

ORCID-Profile: Juan F Combariza-Vallejo, Rocío Orduz-Rodriguez, Natalia Gomez-Lopera, Claudia C Colmenares-Mejia

Zitieren

APA

Combariza-Vallejo, J. F., Orduz-Rodriguez, R., Gomez-Lopera, N., Colmenares-Mejia, C. C., Benavides-Rojas, M. S., Calderon-Ortega, Y. M., Godoy-Corredor, M., & Isaza-Ruget, M. A. (2025). Epidemiology and Survival of Marginal Zone Lymphoma in Colombian Patients: An Observational Retrospective Study. JCO Global Oncology. https://doi.org/10.1200/go-24-00495

Vancouver

Combariza-Vallejo JF, Orduz-Rodriguez R, Gomez-Lopera N, Colmenares-Mejia CC, Benavides-Rojas MS, Calderon-Ortega YM, et al. Epidemiology and Survival of Marginal Zone Lymphoma in Colombian Patients: An Observational Retrospective Study. JCO Global Oncology. 2025. doi:10.1200/go-24-00495

BibTeX
@article{CombarizaVallejo2025,
  author = {Combariza-Vallejo, Juan F and Orduz-Rodriguez, Rocío and Gomez-Lopera, Natalia and Colmenares-Mejia, Claudia C and Benavides-Rojas, Monica S and Calderon-Ortega, Yesica M and Godoy-Corredor, Marcela and Isaza-Ruget, Mario Arturo},
  title = {Epidemiology and Survival of Marginal Zone Lymphoma in Colombian Patients: An Observational Retrospective Study},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-24-00495}
}
Kostenlos starten →